Storz U. The CRISPR Cas patent files, part 1: Cas9 - Where to we stand at the 10 year halftime?
J Biotechnol 2024;
379:46-52. [PMID:
37984590 DOI:
10.1016/j.jbiotec.2023.11.003]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Revised: 11/02/2023] [Accepted: 11/10/2023] [Indexed: 11/22/2023]
Abstract
CRISPR Cas9 has turned out to be one of the most influential technologies in the life sciences. However, ferocious patent debates and an unclear licensing situation makes access to this technology difficult for Small and medium enterprises. This article gives an overview of the status quo 10 years after the seminal patents were filed.
Collapse